Seroconversion of 2009 pandemic influenza A (H1N1) vaccination in kidney transplant patients and the influence of different risk factors

Transplant Infectious Disease

Volumn 15, Issue 6, 2013, Pages 612-618

  Azevedo, L S ^a   Gerhard, J ^a   Miraglia, J L ^b   Precioso, A R ^b   Tavares Timenetsky, M D C S ^c   Agena, F ^a   Gamba, C ^a   Shikanai Yasuda, M A ^a   David Neto, E ^a   Pierrotti, L ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

^c INSTITUTO ADOLFO LUTZ   (Brazil)

Author keywords

A(H1N1)pdm09; Immunosuppression; Influenza; Influenza vaccine; Kidney transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INFLUENZA VACCINE; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS;

2009 H1N1 INFLUENZA; ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; ETHNICITY; FEMALE; FOLLOW UP; GENDER; GLOMERULUS FILTRATION RATE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LYMPHOCYTE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT CARE; PANDEMIC INFLUENZA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL GRAFT DYSFUNCTION; RISK FACTOR; SEROCONVERSION;

A(H1N1)PDM09; IMMUNOSUPPRESSION; INFLUENZA; INFLUENZA VACCINE; KIDNEY TRANSPLANTATION;

ANTIBODIES, VIRAL; AZATHIOPRINE; BRAZIL; CYCLOSPORINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; PANDEMICS; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SIROLIMUS; TACROLIMUS;

EID: 84888874119     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12140     Document Type: Article

References (31)

1. Ison MG. Respiratory viral infections in transplant recipients. Antivir Ther 2007; 12 (4 Pt B): 627-638.
2. Vilchez RA, Fung J, Kusne S. The pathogenesis and management of influenza virus infection in organ transplant recipients. Transpl Infect Dis 2002; 4: 177-182.
3. Vilchez RA, McCurry K, Dauber J, et al. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2002; 2: 287-291.
4. Kumar D, Michaels MG, Morris MI, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010; 10: 521-526.
5. Giezeman KM, Nauta J, Bruijn IA, Palache AM. Trivalent inactivated subunit influenza vaccine Influvac: 25-year experience of safety and immunogenicity. Vaccine 2009; 27: 2414-2417.
6. FDA. Guidance for Industry. Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines, May 2007. US Food & Drug Administration. Available at: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074786.htm
7. Wu J, Xu F, Lu L, et al. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N Eng J Med 2010; 363: 2416-2423.
8. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361: 2405-2413.
9. Strategic Advisory Group of Experts on Immunization-report of the extraordinary meeting on the influenza A (H1N1) 2009 pandemic, 7 July 2009. Wkly Epidemiol Rec 2009; 84: 301-304.
10. Scharpé J, Evenepoel P, Maes B, et al. Influenza vaccination efficacious and safe in renal transplant recipients. Am J Transplant 2008; 8: 332-337.
11. Kotton CN, Hibberd PL. Travel medicine and the solid organ transplant recipient. Am J Transplant 2009; 9 (Suppl 4): S273-S281.
12. Danzinger-Isakov L, Kumar D. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009; 9 (Suppl 4): S258-S262.
13. Blumberg EA, Albano C, Pruett T, et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 1996; 22: 295-302.
14. Candon S, Thervert E, Lebon P, et al. Humoral and cellular immune response after influenza vaccination in kidney transplant recipients. Am J Transplant 2009; 9: 2346-2354.
15. Nailescu C, Xu X, Zhou H, et al. Influenza vaccine after pediatric kidney transplant: a Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol 2011; 26: 459-467.
16. Esposito S, Meregalli E, Daleno C, et al. An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. Nephrol Dial Transplant 2011; 26: 2018-2024.
17. Miraglia JL, Abdala E, Hoff PM, et al. Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients. PLoS ONE 2011; 6: e27214.
18. Kendal AP, Pereira MS, Skehel JJ. Concepts and Procedures for Laboratory-Based Influenza Surveillance. Atlanta, Georgia: Centers for Disease Control and Prevention and Pan American Health Organization; 1982: B17-B35.
19. Zhu FC, Wang H, Fang HH. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361: 2414-2423.
20. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoché MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010; 375: 41-48.
21. Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011; 52: 138-146.
22. Tremblay CL, Rouleau D, Fortin C, et al. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. Vaccine 2011; 29: 1359-1363.
23. Mackay HJ, McGee J, Villa D, et al. Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment. J Clin Virol 2011; 50: 212-216.
24. Salles MJC, Sens YAS, Boas LSV, Machado CM. Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs. Clin Transplant 2010; 24: E17-E23.
25. Mulley WR, Visvanathan K, Hurt AC, et al. Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination. Kidney Int 2012; 82: 212-219.
26. Smith KGC, Isbel NM, Catton MG, Leydon JA, Becker GJ, Walker RG. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant 1998; 13: 160-164.
27. Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus 2005; 14: s2-s8.
28. Keshtkar-Jahroni M, Argani H, Rahnavardi M, et al. Antibody response to influenza immunization in kidney transplant recipients receiving either azathioprine or mycophenolate: a controlled trial. Am J Nephrol 2008; 28: 654-660.
29. Willcocks LC, Chaudhry AN, Smith JC, et al. The effect of sirolimus therapy on vaccine responses in transplant recipients. Am J Transplant 2007; 7: 2006-2011.
30. Struijk GH, Minnee RC, Koch SD, et al. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. Kidney Int 2010; 78: 934-940.
31. Turner AP, Shaffer VO, Araki K, et al. Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in Rhesus macaques. Am J Transplant 2011; 11: 613-618.